MedTrace Logo

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

NCT07195825 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and tolerability of BBM-P002 for stereotactic injection to treat participants with idiopathic Parkinson's Disease (PD) during the dose-limiting toxicity (DLT) observation period.

Conditions

  • PD

Interventions

GENETIC

Injecting BBM-P002 into the bilateral putamen

BBM-P002 is an AAV-based gene therapy that delivers a therapeutic gene cassette into putamen for the treatment of Parkinson's Disease

Sponsors & Collaborators

  • Shanghai Xinzhi BioMed Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jun Liu, MD · Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

  • Jing Sun, MD · Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-27
Primary Completion
2027-12-30
Completion
2031-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07195825 on ClinicalTrials.gov